沙利度胺联合氩氦刀治疗中晚期肝癌临床观察  

Clinical observation of Thalidomide combined with percutaneous cryoablation on treating advanced primary liver cancer

作　　者：刘涛[1] 米彦军[1] 张雅雅[1] 邱国钦[1] 郭春华[1] 林智才[1] 

机构地区：[1]解放军第174医院肿瘤科,福建厦门361003

出　　处：《临床军医杂志》2013年第4期352-354,共3页Clinical Journal of Medical Officers

摘　　要：目的探讨沙利度胺(TLD)联合氩氦刀治疗中晚期原发性肝癌的临床疗效及不良反应。方法将50例中晚期肝癌患者分为观察组和对照组,每组各25例。观察组在氩氦刀基础上加口服TLD,对照组不用TLD。结果 TLD联合氩氦刀治疗中晚期原发性肝癌的近期临床疗效及不良反应显示:观察组肿瘤完全缓解(CR)2例,部分缓解(PR)20例,无变化(NC)2例,进展(PD)1例,总有效率为88%;对照组肿瘤完全缓解(CR)1例,部分缓解(PR)13例,无变化(NC)5例,进展(PD)6例,总有效率为56%(P<0.05)。两组均未见严重不良反应发生。随访3年,观察组1、2、3年生存率分别为80%、64%、44%;对照组分别为48%、32%、16%(P<0.05)。结论应用TLD与氩氦刀联合治疗中晚期原发性肝癌能延长患者生存时间,不良反应轻,是治疗中晚期肝癌的一种有效方法。Objective To explore the efficacy and the adverse effects of Thalidomide （TLD） in treatment of advanced primary liver cancer after percutaneous eryoablation （PTC）. Methods Fifty patients with advanced primary liver cancer were divided into trial group and control group （n = 25/group） at random. The trial group was treated with oral TLD after PTC, and the control group was treated with PTC alone. Results The overall response rate of the trial group was 88.0% , with complete remission （CR） in 2, partial remission （PR） in 20, no change （NC） in ：2 and progressive development （PD） in 1 patient（s） , and that of the control group was 56% , with CR in 1 , PR in 13, NC in 5 and PD 6 patients （P 〈0.05）. Adverse effects were less and tolerated. Ac- cording to the follow-up up to 3 years, the 1-, 2- and 3-year survival rate of the trial group was 80% , 64% and 44% , and that of control group was 48% , 32% and 16% , respectively （P 〈 0.05）. Conclusion Treatment of TLD combined with PTC can prolong the survival time of advanced primary liver cancer patients with less adverse effects.

关 键 词：原发性肝癌 沙利度胺 氩氦刀 

分 类 号：R735.7[医药卫生—肿瘤]